Results 61 to 70 of about 41,454 (219)

Willingness-to-pay for a hypothetical Ebola vaccine in Indonesia: A cross-sectional study in Aceh [version 3; peer review: 3 approved, 1 not approved]

F1000Research, 2023
Background: Some Ebola vaccines have been developed and tested in phase III clinical trials. However, assessment of whether public have willingness to purchase or not, especially in unaffected areas, is lacking.
Samsul Anwar, Mudatsir Mudatsir, Amanda Yufika, Jonny Karunia Fajar, Salwiyadi Salwiyadi, Muhammad N. Ferdian, Roully Azhars, Harapan Harapan, Aga S. Imanda, Arya U. Timur, Darul Ilham, Ricky Yordani, Juwita Sahputri, Yogambigai Rajamoorthy, Setia Pramana, Kurnia F. Jamil, Abram L. Wagner   +16 more
doaj   +1 more source

Beyond Privacy Calculus: Understanding Digital Contact Tracing Acceptance Through Surveillance Drift and Agency Theory

Canadian Journal of Administrative Sciences / Revue Canadienne des Sciences de l'Administration, Volume 43, Issue 2, June 2026.
ABSTRACT Digital contact tracing (DCT) has emerged as a promising tool for controlling infectious disease outbreaks, yet its adoption has been hampered by widespread privacy concerns. Prior research studies mainly rely on privacy calculus theory. We extend this view by integrating agency theory to explain how delegating sensitive data to government ...
Félix Joly, Camille Grange, Renaud Legoux   +2 more
wiley   +1 more source

Remdesivir for the Treatment of COVID-19: A Systematic Review of the Literature [PDF]

, 2020
In March 2020, the World Health Organization declared the spread of SARS-CoV-2 a global pandemic. To date, coronavirus disease-2019 (COVID-19) has spread to over 200 countries, leading to over 1.6 million cases and over 99,000 deaths. Given that there is
Aly, Besma, Baron, David A., Blodget, Emily, Hashemi, Areio, Kouyoumjian, Sarkis, Musa, Arif, Pendi, Kasim, Stevens, Susan, Warbasse, Elizabeth, Yousif, Jenna   +9 more
core  

Molecular characterization of Ebola virus, immune response, and therapeutic challenges: a narrative review

Egyptian Journal of Medical Human Genetics
The Ebola virus (EBOV) remains a major public health challenge due to its complex structure and the lack of appropriate and effective vaccines and therapies.
Martin Ndayambaje, Callixte Yadufashije, Thierry Habyarimana, Theogene Niyonsaba, Hicham Wahnou, Patrick Gad Iradukunda, Cedrick Izere, Olivier Uwishema, Pacifique Ndishimye, Mounia Oudghiri   +9 more
doaj   +1 more source

The Ebola Vaccine, Iatrogenic Injuries, and Legal Liability. [PDF]

PLoS Medicine, 2015
Amir Attaran and Kumanan Wilson propose a compensation system for vaccine injuries, based on no-fault principles, to ensure that recipients of Ebola vaccines are fairly compensated in cases of iatrogenic harm.
Amir Attaran, Kumanan Wilson
doaj   +1 more source

Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection

Frontiers in Immunology, 2021
Ebola viruses are enveloped, single-stranded RNA viruses belonging to the Filoviridae family and can cause Ebola virus disease (EVD), a serious haemorrhagic illness with up to 90% mortality.
Stephanie Longet, Jack Mellors, Miles W. Carroll, Miles W. Carroll, Tom Tipton   +4 more
doaj   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1650-1661, June 2026.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J. Else, Lauren Walker, Colin Hale, Victoria Shaw, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani, Margaret Irwin, Yvanne Enever, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G. Lalloo, Michael Jacobs, Julian A. Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H. Khoo, Thomas E. Fletcher, on behalf of the AGILE CST‐6 Study Group, Shazaad Ahmad, Christopher J. Edwards, Lesley Dry, Georgie McKenzie, Aleksandra Ros, Michael Stackpoole, Laura Bradley, Karen Jennings‐Wilding, Nicholas Paton, Fred Hayden, Janet Darbyshire, Amy Lucas, Ulrika Lorch, Andrew Freedman, Richard Knight, Steven Julious   +48 more
wiley   +1 more source

The risk of transmission of a viral haemorrhagic fever infection in a United Kingdom laboratory [PDF]

, 2017
No abstract ...
Shorten, Robert J., Wilson-Davies, Eleri
core   +2 more sources

Quantification of heterogeneity in human CD8+ T cell responses to vaccine antigens: an HLA-guided perspective

Frontiers in Immunology
Vaccines have historically played a pivotal role in controlling epidemics. Effective vaccines for viruses causing significant human disease, e.g., Ebola, Lassa fever, or Crimean Congo hemorrhagic fever virus, would be invaluable to public health ...
Duane C. Harris, Apoorv Shanker, Makaela M. Montoya, Trent R. Llewellyn, Anna R. Matuszak, Aditi Lohar, Jessica Z. Kubicek-Sutherland, Ying Wai Li, Kristen Wilding, Ben Mcmahon, Sandrasegaram Gnanakaran, Ruy M. Ribeiro, Alan S. Perelson, Carmen Molina-París   +13 more
doaj   +1 more source

Ebola virus disease: Recent advances in diagnostics and therapeutics

Asian Pacific Journal of Tropical Medicine, 2019
Ebola virus disease (EVD) is associated with haemorrhagic fever in humans and nonhuman primates, with a high rate of fatality (up to 90%). Some outbreaks in human history have proven the lethality of EVD.
Supriya Jagga, Ashish Ranjan Sharma, Chiranjib Chakraborty, Sang-Soo Lee   +3 more
doaj   +1 more source